Can hyperthyroidism cause gynaecomastia? Yes — an overactive thyroid is a recognised endocrine cause of breast tissue enlargement in men. Excess thyroid hormones disrupt the balance between oestrogen and androgens, raising the relative level of free oestrogen and stimulating glandular breast tissue growth. Understanding this hormonal link is important for men who notice unexplained breast changes, particularly when accompanied by other symptoms of thyroid overactivity. This article explains the mechanisms involved, what to look out for, how the diagnosis is made, and what treatment options are available under UK clinical guidance.

How Hyperthyroidism Affects Hormone Balance in Men

Hyperthyroidism raises SHBG levels, disproportionately reducing free testosterone relative to free oestrogen, and enhances peripheral aromatisation — together shifting the oestrogen-to-androgen ratio in favour of oestrogen.

Have any more questions about this? Message our pharmaceutical team to get more info →

Hyperthyroidism occurs when the thyroid gland produces excessive amounts of thyroid hormones — primarily thyroxine (T4) and triiodothyronine (T3). In men, this hormonal excess can disrupt the delicate balance between oestrogen and androgens (male sex hormones such as testosterone), which is essential for maintaining normal breast tissue.

Thyroid hormones influence the liver's production of sex hormone-binding globulin (SHBG). When thyroid hormone levels are elevated, SHBG concentrations rise significantly. SHBG binds both testosterone and oestradiol, but does so with a higher affinity for testosterone. As a result, a greater proportion of testosterone becomes bound and biologically inactive, whilst the relative reduction in free oestradiol is smaller. This disproportionate effect effectively lowers the amount of free testosterone available in the bloodstream relative to free oestrogen.

Additionally, hyperthyroidism can enhance the peripheral conversion of androgens to oestrogens through a process called aromatisation, which occurs in adipose (fat) tissue, the liver, and other organs. The net result is a shift in the oestrogen-to-androgen ratio — a key hormonal mechanism that can promote the development of gynaecomastia. It is worth noting that subclinical hyperthyroidism may produce subtler hormonal effects, though the same mechanisms apply. Understanding this endocrine interplay is important for clinicians and patients alike when investigating unexplained breast tissue changes in men.

Relevant UK guidance includes NICE NG145 (Thyroid disease: assessment and management) and the NHS patient information on overactive thyroid.

The Link Between Hyperthyroidism and Gynaecomastia

Hyperthyroidism is an established endocrine cause of gynaecomastia, occurring in an estimated 10–40% of affected men; treating the thyroid condition typically leads to resolution of breast tissue changes over several months.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — has several recognised causes, and hyperthyroidism is one of the established endocrine conditions associated with it. Observational studies suggest that gynaecomastia may occur in approximately 10–40% of men with untreated or poorly controlled hyperthyroidism, though estimates vary considerably across studies depending on study design, severity of thyroid dysfunction, and how gynaecomastia is defined and assessed.

The primary mechanism, as outlined above, involves an altered oestrogen-to-androgen ratio. Elevated oestrogen activity stimulates oestrogen receptors in breast ductal tissue, leading to proliferation of glandular tissue beneath the nipple-areolar complex. This is distinct from pseudogynaecomastia, which refers to fatty tissue accumulation without true glandular enlargement and is not hormonally driven in the same way.

It is worth noting that hyperthyroidism is not the most common cause of gynaecomastia — other causes include puberty, obesity, medications (such as spironolactone, cimetidine, or anabolic steroids), liver disease, and hypogonadism. However, thyroid dysfunction should always be considered as part of a thorough diagnostic work-up, particularly when gynaecomastia presents alongside other symptoms of thyroid overactivity.

Identifying and treating the underlying hyperthyroidism often leads to resolution or significant improvement of the gynaecomastia over time, typically over several months once euthyroidism (normal thyroid function) is achieved. Gynaecomastia that has been present for more than 12 months is more likely to have undergone fibrotic change and may be less likely to regress fully with medical treatment alone.

Symptoms and Signs to Discuss With Your GP

Men with gynaecomastia alongside palpitations, unintentional weight loss, heat intolerance, tremor, or anxiety should discuss thyroid overactivity with their GP promptly; urgent attention is needed for chest pain or severe palpitations.

Men who notice breast tissue enlargement or tenderness should not dismiss it as insignificant. Gynaecomastia typically presents as a rubbery or firm disc of tissue beneath one or both nipples, which may be tender to touch. It is important to distinguish this from other causes of breast changes, including rare but serious conditions such as male breast cancer, which may present as a hard, irregular, or unilateral lump with associated skin changes or nipple discharge.

If hyperthyroidism is the underlying cause, other symptoms are likely to be present alongside gynaecomastia. These may include:

• Unintentional weight loss despite a normal or increased appetite

• Palpitations or a rapid, irregular heartbeat

• Heat intolerance and excessive sweating

• Tremor of the hands

• Anxiety, irritability, or difficulty sleeping

• Increased frequency of bowel movements

• Fatigue or muscle weakness

• A visibly enlarged thyroid gland (goitre)

Not all men with hyperthyroidism will experience every symptom, and in older adults the presentation can be more subtle — sometimes referred to as 'apathetic hyperthyroidism'. If you notice breast changes alongside any of the above symptoms, it is important to discuss them with your GP promptly.

Seek urgent medical attention (same day or via 999/A&E as appropriate) if you experience severe palpitations, chest pain, breathlessness, or near-fainting, as these may indicate a cardiac complication of thyrotoxicosis such as atrial fibrillation requiring prompt assessment.

For breast symptoms specifically, NICE guidance (NG12: Suspected cancer: recognition and referral) sets out criteria for urgent referral. Any man with a suspicious breast lump should be assessed promptly, and your GP can refer you via the urgent suspected cancer pathway if indicated. Early identification of the underlying cause allows for timely investigation and appropriate management.

Diagnosing the Underlying Cause of Gynaecomastia

Diagnosis requires thyroid function tests (TSH, free T4, free T3), sex hormone panel, and liver function tests; further investigations such as thyroid antibodies or isotope scan are arranged if hyperthyroidism is confirmed.

When a man presents with gynaecomastia, a structured diagnostic approach is essential to identify the underlying cause. The GP will typically begin with a thorough clinical history — including medication use, alcohol intake, recreational drug use, and any symptoms suggestive of systemic illness — followed by a physical examination of the breast tissue, testes, and thyroid gland.

Blood tests form the cornerstone of investigation and should include:

• Thyroid function tests (TFTs): TSH (thyroid-stimulating hormone) is the primary screening test; a suppressed TSH with elevated free T4 and/or free T3 confirms hyperthyroidism

• Sex hormones: Testosterone, oestradiol, LH (luteinising hormone), and FSH (follicle-stimulating hormone) to assess gonadal function; SHBG may also be measured to help assess free androgen status

• Prolactin: If hyperprolactinaemia is clinically suspected

• Liver function tests: Liver disease can impair oestrogen metabolism

• Renal function and electrolytes

• Beta-hCG and alpha-fetoprotein (AFP): To exclude testicular germ cell tumours if a testicular mass is suspected on examination; for suspected adrenal or other endocrine tumours, targeted hormonal tests (such as DHEAS or cortisol) may be considered based on clinical findings

If thyroid disease is confirmed, further tests such as thyroid antibodies (for Graves' disease) or a thyroid isotope scan may be arranged, often via an endocrinology referral, in line with NICE NG145. For breast symptoms, NICE NG12 (Suspected cancer: recognition and referral) and NICE CKS (Gynaecomastia) support a systematic approach in primary care, including when to refer urgently. Any uncertainty about the nature of breast tissue changes should prompt referral to a breast clinic or endocrinologist. Scrotal ultrasound is indicated if a testicular mass is suspected on examination; breast ultrasound may also be requested depending on clinical findings.

Treatment Options and Managing Both Conditions

First-line UK treatment for hyperthyroidism is carbimazole per NICE NG145; restoring euthyroidism usually resolves gynaecomastia, with tamoxifen or surgery considered for persistent cases under specialist guidance.

The management of hyperthyroidism-related gynaecomastia centres primarily on treating the thyroid condition itself. Once thyroid hormone levels are restored to normal, the hormonal imbalance driving breast tissue growth is corrected, and gynaecomastia often improves or resolves — though this may take several months.

In the UK, the main treatment options for hyperthyroidism include:

• Beta-blockers (e.g., propranolol): Used for short-term symptomatic relief of thyrotoxicosis symptoms such as palpitations, tremor, and anxiety, whilst awaiting the effect of definitive treatment. This is recommended in NICE NG145 and British Thyroid Association (BTA) guidance.

• Antithyroid medications: Carbimazole is the first-line agent recommended by NICE NG145 and the BTA. It works by inhibiting thyroid hormone synthesis. Propylthiouracil (PTU) is reserved for specific situations, such as intolerance to carbimazole; it carries a risk of serious hepatotoxicity and should be used with caution. Important safety advice: Patients taking carbimazole or PTU should be told to stop the medication immediately and seek urgent medical attention if they develop a sore throat, mouth ulcers, fever, or other signs of infection, as these may indicate agranulocytosis (a serious reduction in white blood cells). Signs of liver problems — such as jaundice, dark urine, or persistent nausea — should also be reported promptly. Full prescribing information is available in the relevant Summary of Product Characteristics (SmPC) on the electronic Medicines Compendium (eMC).

• Radioactive iodine (RAI) therapy: A definitive treatment that destroys overactive thyroid tissue. It is commonly used in Graves' disease and toxic nodular goitre.

• Thyroidectomy: Surgical removal of part or all of the thyroid gland, considered when other treatments are unsuitable or when a goitre is causing compressive symptoms.

If gynaecomastia persists despite successful treatment of hyperthyroidism, additional options may be considered. Medications such as tamoxifen (an oestrogen receptor antagonist) or raloxifene have been used off-label — meaning outside their licensed indications — for gynaecomastia, usually initiated by a specialist. Evidence is limited, and these are generally considered in early, painful gynaecomastia rather than longstanding fibrotic cases. For gynaecomastia that does not respond to medical treatment, surgical correction (subcutaneous mastectomy) may be appropriate.

Patients are encouraged to report any suspected side effects from medicines to the MHRA via the Yellow Card Scheme (available at yellowcard.mhra.gov.uk). All treatment decisions should be made in partnership with the relevant specialist — typically an endocrinologist and, where needed, a breast surgeon.

When to Seek Further Medical Advice

Seek prompt GP review for any hard, irregular, unilateral, or rapidly growing breast lump, nipple discharge, or skin changes, as NICE NG12 supports urgent 2-week-wait referral to exclude male breast cancer.

Most cases of gynaecomastia are benign, but certain features warrant prompt medical attention. You should contact your GP without delay if you notice:

• A hard, irregular, or rapidly growing lump in the breast tissue

• Nipple discharge, particularly if bloodstained

• Skin changes over the breast, such as dimpling, puckering, or redness

• A unilateral lump that does not feel like typical gynaecomastia

• Symptoms of hyperthyroidism such as palpitations, significant weight loss, or tremor that are new or worsening

These features may indicate conditions requiring urgent investigation, including male breast cancer or a hormone-secreting tumour. NICE NG12 (Suspected cancer: recognition and referral) sets out criteria for urgent 2-week-wait referral for suspicious breast symptoms in men, and your GP can refer you via this pathway if appropriate. Although male breast cancer is rare — accounting for less than 1% of all breast cancer cases in the UK — it should not be overlooked.

Seek urgent medical attention (via 999 or A&E) if you experience severe palpitations, chest pain, breathlessness, or fainting, as these may indicate a cardiac complication of thyrotoxicosis requiring immediate assessment.

If you have already been diagnosed with hyperthyroidism and are receiving treatment, but your gynaecomastia is not improving or is causing significant physical discomfort or psychological distress, raise this with your endocrinologist or GP. Psychological impact should not be underestimated; body image concerns are valid and support is available.

For further information, reliable UK resources include the NHS website (including NHS pages on overactive thyroid and gynaecomastia), the British Thyroid Foundation (BTF), and NICE guidelines (including NG145 and NG12). Always seek personalised advice from a qualified healthcare professional rather than relying solely on general information, as individual circumstances vary considerably.

Frequently Asked Questions